This is a summary of the European public assessment report (EPAR) for Fulvestrant Mylan. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Fulvestrant Mylan. For practical information about using Fulvestrant Mylan, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Fulvestrant is indicated for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women: - not previously treated with endocrine therapy, or - with disease relapse on or after adjuvant anti-estrogen therapy, or disease progression on antiestrogen therapy.
Therapeutic Area (MeSH)
ATC Code
L02BA03
ATC Item
fulvestrant
Pharmacotherapeutic Group
Endocrine therapy
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| fulvestrant | N/A | 氟维司群 |
EMA Name
Fulvestrant Mylan
Medicine Name
Fulvestrant Mylan
Aliases
N/ANo risk management plan link.
